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Key Points
Question: What is the risk of cause-specific unnatural mortality in people with 
epilepsy and what is the contribution of medication to these deaths? 
Findings: People with epilepsy, identified from the general population, are at three-
fold increased risk of any unnatural mortality compared to those without. A five-fold 
increased risk was observed for accidental medication poisoning. Psychotropic 
medication and opioids were the medication groups most commonly used in 
poisoning deaths, not antiepileptic drugs.
Meaning: Clinicians should provide advice on accident and suicide prevention and 
consider toxicity of concomitant medication when prescribing for people with 
epilepsy.
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Abstract
Importance: People with epilepsy are at increased risk of mortality, but the cause-
specific risks of all unnatural causes have not been reported. 
Objective: Estimate cause-specific unnatural mortality risks in people with epilepsy, 
and identify the medication types involved in poisoning deaths.
Design: Cohort studies in two electronic primary care datasets, linked to 
hospitalization and mortality records. Each person with epilepsy was matched to up 
to twenty individuals without epilepsy on age (+/-2 years), gender and general 
practice. 
Setting: The Clinical Practice Research Datalink (CPRD) in England (01/01/1998-
31/03/2014) and the Secure Anonymised Information Linkage (SAIL) Databank in 
Wales (01/01/2001-31/12/2014). 
Participants: We identified 44,678 (CPRD) and 14,051 (SAIL Databank) individuals 
in the prevalent epilepsy cohorts and 891,429 (CPRD) and 279,365 (SAIL Databank)
individuals in the comparison cohorts. 
Exposure: People with epilepsy were identified from primary care epilepsy 
diagnoses and associated antiepileptic drug (AED) prescriptions.
Main Outcomes and Measures: Unnatural mortality was coded by the International 
Statistical Classification of Diseases and Related Health Problems 10th Revision 
(ICD-10) codes V01-Y98 in Office for National Statistics (ONS) mortality records. We
estimated hazard ratios in each dataset using stratified-Cox proportional hazards 
models and meta-analysed these using the DerSimonian and Laird random effects 
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model. The frequency at which each medication type was involved was estimated as
a percentage of all medication poisoning deaths.
Results: People with epilepsy were more likely to die from any unnatural cause (HR,
2.77, 95%CI 2.43-3.16), accident (HR, 2.97, 95%CI, 2.54-3.48) or suicide (HR, 2.15, 
95%CI 1.51-3.07) than the comparison cohort. We observed particularly large risk 
elevations for accidental medication poisoning (HR, 4.99, 95%CI 3.22-7.74) and 
intentional self-poisoning with medication (HR, 3.55, 95%CI 1.01-12.53). Opioids 
(56.5%, 95%CI 43.3%-69.0%) and psychotropic medication (32.3%, 95%CI 20.9%-
45.3%) were more commonly involved in poisoning deaths among people with 
epilepsy than antiepileptic drugs (9.7%, 95%CI 3.6%-19.9%).
Conclusions and Relevance: People with epilepsy are at increased risk of 
unnatural death versus people without epilepsy. They should be adequately advised 
about accident prevention and monitored for suicidal ideation, thoughts and 
behaviours. The suitability and toxicity of concomitant medication should be 
considered when prescribing for comorbid conditions.
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Introduction 
People diagnosed with epilepsy are two-to-three times more likely to die prematurely
compared to the rest of the population. The degree to which this risk is elevated 
varies by cause of death.1, 2 Earlier research has focused on sudden unexpected 
death in epilepsy (SUDEP), with less attention paid to other causes. A recent ‘Call 
for Action’ identified the need to better understand cause-specific mortality risk, 
particularly for unnatural causes (i.e. accident, suicide, homicide and iatrogenic 
effects), in people with epilepsy.3 Furthermore, the need for accurate identification of 
epilepsy and cause of death in epidemiologic studies, has been emphasized.4
Several secondary care-based observational studies have reported two-to-five fold 
increased risks of unnatural mortality.1, 5, 6 Some examined risk by type of accident,5, 6
one reported method of suicide in people with epilepsy,7 but none comprehensively 
reported risks across the full range of suicide and accident types. A previous study of
suicide from the US National Violent Death Reporting System reported that 
antiepileptic drugs (AEDs) were taken in just 6% of intentional poisoning deaths in 
epilepsy.7 This contrasts with a study of non-fatal self-poisoning, where AEDs were 
the most commonly taken medication type in people with epilepsy (27%).8
We aimed to estimate relative risks of specific causes of unnatural mortality in 
people with epilepsy versus a matched comparison cohort without epilepsy. We 
utilized two linked primary care-mortality databases to accurately estimate risks of 
cause-specific unnatural mortality. We also examined how frequently specific types 
of medication were involved in medication poisoning deaths.
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Methods
 Design, Setting and Participants
We conducted two population-based cohort studies in the (1) Clinical Practice 
Research Datalink (CPRD) and the (2) Secure Anonymised Information Linkage 
(SAIL) Databank. The CPRD is a general practice database which covers 
approximately 7% of the UK population. It contains anonymized patient-level data 
including demographics, diagnoses, test results and prescribed treatments.9 We 
used the July 2015 release, which included 13,979,404 patients whose data was 
deemed to be of acceptable research quality standards, from 689 practices.  It is 
deemed representative of the age, gender and ethnicity distributions of the UK 
population.9 We identified the epilepsy and comparison cohorts from a subset of 
practices whose anonymized patient data were linked to the following additional data
sources: Office for National Statistics (ONS) mortality records, Index of Multiple 
Deprivation (IMD) 2010 and Hospital Episode Statistics (HES). These sources 
provide information on cause of death, quintiles of deprivation based on the patient’s 
postcode and inpatient hospitalizations, respectively.9 All of the linked practices were
in England and comprised 74% of the English practices in the CPRD. 
The SAIL Databank contains data from 13 health and social care databases in 
Wales. Data from individuals is anonymously linked between databases though a 
unique identifier.10 The general practice dataset (GPD) contains diagnostic, 
treatment and test data from 360 (76%) of general practices in Wales 
(n=4,052,388).11 Hospital admission diagnoses and discharge dates are detailed in 
the Patient Episode Database for Wales (PEDW). The Annual District Death Extract 
(ADDE) provides ONS data on date and cause of death.12 There was no overlap 
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between the practices included in the CPRD and the SAIL Databank cohorts 
because none of the Welsh practices in the CPRD were in the subset eligible for 
data linkage. 
The  Independent  Scientific  Advisory  Committee  (ISAC)  of  the  Medicine  and
Healthcare Regulatory Agency (MHRA) approved access to the CPRD and linked
data (protocol 15_046RA2R). Approval was granted to access the SAIL Databank
from  the  Information  Governance  Review  Panel  (IGRP),  an  independent  body
consisting of a range of government, regulatory and professional agencies, which
oversees  study  approvals  in  line  with  ethical  permissions  already  granted  for
conducting data analysis in the SAIL Databank (approval number 0204).10,13 Informed
consent is not required for use of these anonymised datasets.  This study is reported
in  accordance  with  the  REporting  of  studies  Conducted  using  Observational
Routinely-collected health Data (RECORD) Statement.14
The International League against Epilepsy (ILAE) recommend the presence of both a
diagnostic code for epilepsy and an AED treatment code for reliable ascertainment of
epilepsy in epidemiologic studies.15 We therefore adopted this definition. Epilepsy 
diagnoses are recorded in the CPRD and the GPD using the Read code system 
version 2.16 Code lists were produced by searching for epilepsy-related terms in the 
CPRD medical dictionary. This list was refined following discussion with a 
neurologist and in comparison with studies previously conducted in the CPRD17, 18 
and the SAIL Databank.19 A list of AEDs licensed in the UK was produced by one 
pharmacist (HCG) and checked by another (DMA), based on drugs listed in the 
British National Formulary (BNF 68).20 
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We defined the epilepsy index date as the latest date at which a person had received
both an epilepsy diagnostic code plus an associated AED prescription. The AED 
prescription could be issued in the month before or up to 6 months after the date of 
the diagnostic code. We required the index date to be within the study periods, which
we defined based on corresponding linkage availability. This was 01/01/1998-
03/31/2014 for the CPRD and 01/01/2001-12/31/2014 for the SAIL Databank. 
Follow-up began on the index date which occurred after registration of the patient in 
a practice. Separately in the CPRD and SAIL Databank, we matched people with 
epilepsy to up to 20 individuals who had never received a diagnostic code for 
epilepsy and were alive on the date that follow-up began (online material). We 
matched these comparison cohorts to their respective epilepsy cohorts on gender, 
year of birth (+/- 2 years) and general practice (Figure 1). Members of the 
comparison cohorts were followed up from the same day as the individual they were 
matched to in the epilepsy cohort.
We followed the epilepsy and comparison cohorts until the earliest date of: death; 
transfer out of the practice; end of data collection from the practice; or study end. In 
the SAIL Databank, it was possible to follow patients who transferred to other 
practices.
We identified diagnoses and treatments using general practice data. We used 
published Read code lists to identify patients diagnosed with a range of mental 
illnesses.21, 22 Our code lists for migraine, neuropathic pain and substance misuse 
were verified by two General Practitioners and are available along with the epilepsy 
and AED codes at www.ClinicalCodes.org.23 Hospital discharge diagnoses were 
identified using the International Statistical Classification of Diseases and Related 
Health Problems 10th Revision (ICD-10) coding system.24 
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Cause-specific Mortality Outcomes
We determined cause of death from the ONS-recorded underlying cause of death, 
as coded by ICD-10. We used the following codes to identify unnatural death (V01-
Y98): transport accidents (V01-99, Y85), other accidents (W00-99, X00-39, X50-59, 
Y86), accidental poisoning with medication (X40-44), any accidental poisoning (X40-
49), intentional self-poisoning with medication (X60-64, Y10-14), any intentional self-
poisoning (X60-69, Y15-19), other suicide (X70-84, Y20-34, excluding Y33·9), 
homicide (X85-Y09, Y33·9, Y87·1) and iatrogenic effects (Y40-84, Y88). We included
events of undetermined intent in suicide estimates as per UK convention, because 
most of these deaths are likely to be suicides.25 We identified specific types of 
medication involved in poisoning deaths according to codes T36-50 in 
supplementary causes of death fields (eTable 1).
Statistical Analysis
We applied a common protocol to conduct separate analyses in the two databases 
using Stata version 13 (StataCorp,College Station,Texas). Baseline characteristics 
were reported as numerical and percentage frequencies, medians or means and 
compared using Student’s t-tests, Mann-Whitney U tests or Chi-squared tests, as 
appropriate. We examined the proportion of individuals per cohort with mental health
diagnoses, neuropathic pain or migraine, before or after cohort entry. We calculated 
mortality rates by dividing the number of events by the sum of person-years at risk. 
We accounted for the matched design by fitting stratified-Cox proportional hazards 
models to estimate unadjusted and adjusted hazard ratios for specific causes of 
death. Proportionality assumptions were checked using a test for Schoenfeld 
residuals and visually by graphical inspection. Adjustments were made for area-level
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deprivation because people with epilepsy are known to reside in more deprived 
areas than those without,19 which may independently increase risk of death. 
Deprivation was recorded by quintiles using the Index of Multiple Deprivation (IMD-
2010) in CPRD and the Welsh Index of Multiple Deprivation (WIMD) in the SAIL 
Databank. Where level of deprivation was missing, individuals were assigned to an 
‘unknown’ category. 
We meta-analyzed the hazard ratios estimated from each dataset using the 
DerSimonian and Laird random effects model implemented via the metan command 
in Stata.26 Additionally, we restricted the cohorts to the incident epilepsy and 
comparison cohorts and estimated risks for the four main subgroups (all-cause 
mortality, unnatural death, accident and suicide). The purpose of this sensitivity 
analysis was to explore whether there was evidence of survival bias in using the 
prevalent cohort for our primary analysis. We also produced Kaplan-Meier survival 
estimates for all unnatural death separately for the two datasets, accounting for 
competing risks. The frequency of involvement of each medication type in poisoning 
deaths were pooled across the CPRD and SAIL Databank and reported as 
percentages of all poisoning deaths for the prevalent cohorts.
Results
We matched 44,678 people with epilepsy to 891,429 persons without epilepsy in the 
CPRD and 14,051 people with epilepsy to 279,365 individuals without epilepsy in the
SAIL Databank (Figure 1). The baseline characteristics are described in Table 1. In 
both datasets, 51% of the epilepsy and comparison cohorts were male. The median 
age on entry was 40 (IQR 25-60) in the CPRD and was 43 (IQR 24-64) in the SAIL 
Databank. With the exception of neuropathic pain, people with epilepsy were more 
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likely to have been diagnosed with any of the comorbid conditions examined at 
baseline, to have been treated with psychotropic medication, and to have higher 
levels of deprivation, than the comparison cohort (p<0.05). People with epilepsy 
were also more likely have recorded a new mental illnesses diagnosis during follow-
up. The comparison cohorts had longer follow-up than the epilepsy cohort (CPRD 
5.1 vs. 4.0 years; SAIL Databank 7.7 vs. 6.9 years), and follow-up ended more 
commonly due to death in the epilepsy cohorts (CPRD 14.7% vs 7.1%; SAIL 
Databank 15.3% vs 8.4%). 
Counts and rates for each unnatural cause of death are presented separately for the 
two datasets in Table 2. The meta-analyzed hazard ratios for cause-specific 
unnatural mortality, adjusted for area-level deprivation, are presented in Figure 2. 
These estimates were similar to the unadjusted estimates. Compared to persons 
without the condition, people with epilepsy were at an increased risk of unnatural 
mortality (deprivation-adjusted HR 2.77, 95% CI, 2.43-3.16). We observed this 
elevated risk for both accidental death (deprivation-adjusted HR 2.97, 95% CI, 2.54-
3.48), which represented the majority of unnatural deaths (Table 2), and suicide 
(deprivation-adjusted HR 2.15, 95% CI, 1.51-3.07). The pooled relative risks for 
homicide (deprivation-adjusted HR 3.51, 95%CI, 1.16-10.57) and iatrogenic fatalities 
(deprivation-adjusted HR 4.77, 95%CI, 2.47-9.22) were also elevated, albeit with 
wide confidence intervals for these exceptionally rare causes of death. 
Pooled across the two databases, 22.8% (95%CI, 18.0-28.3%) of unnatural deaths 
were medication poisonings in the epilepsy cohorts compared to 11.2% (95%CI, 
10.0-12.6%) in the comparison cohorts. The medication types most commonly taken 
in poisoning deaths were opioids (epilepsy cohorts 56.5%, 95%CI, 43.3-69.0%; 
comparison cohorts 47.3%, 95%CI, 41.4-53.3%) and psychotropic medication 
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(epilepsy cohorts 32.3%, 95%CI, 20.9-45.3%; comparison cohorts 36.7%, 95%CI, 
31.0-42.6%). By contrast, AEDs were taken in relatively few medication poisoning 
deaths (epilepsy cohort 9.7%, 95%CI 3.6-19.9%; comparison cohort 2.5%, 95%CI, 
1.0-5.1%).
Sensitivity analysis identified 14,057 people with incident epilepsy and 263,610 in the
comparison cohort in the CPRD, and 7,274 people with incident epilepsy and 
144,287 in the comparison cohort in the SAIL Databank. The hazard ratios estimated
from meta-analysis of the incident cohorts were similar to those estimated from the 
prevalent cohorts (Figure 3). The cause-specific survival rate after five years were 
99.7% (95%CI 99.5%-99.8%) and 99.8% (99.8%-99.8%) for the epilepsy and 
comparison cohorts respectively in the CPRD; and 99.5% (95%CI 99.3%-99.7%) 
and 99.8% (95%CI 99.8%-99.8%), in the SAIL Databank (eFigure 1, eFigure 2).
 Discussion 
Across two linked-primary care and mortality databases, people with epilepsy had 
increased risk of all types of unnatural mortality compared to those without epilepsy. 
In both people with epilepsy and a matched comparison cohort, psychotropic 
medication and opioids were the medicine groups most commonly used in poisoning 
deaths, with AEDs much less frequently reported. To our knowledge, this is the first 
study to comprehensively examine cause-specific unnatural mortality risks, including 
both accidental and intentional medication poisoning separately, in people with 
epilepsy. 
Our relative estimates for all unnatural death, accidental death and suicide, are in the
same direction, but generally lower, than those recorded in studies conducted using 
secondary care records.5, 6, 27 Fazel et al. observed an odds ratio of 3.6 (95% CI, 3.3-
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4.0) for all external injury, 3.5 (95% C,I 3.3-4.2) for suicide and 3.6 (95% CI 3.1-4.1) 
for accident.5  Christensen et al. also reported a slightly higher risk of suicide (RR 
3.17, 95%CI 2.88-3.50).27 Standardized mortality ratios (SMR) of 5.6 (95% CI 5.0-
6.3) for injury and poisoning, and 3.5 (95% CI 2.6-4.6) for suicide, were reported by 
Nilsson et al.6  These studies defined epilepsy populations from hospital records,5, 6, 27
most of which comprised inpatient episodes with some outpatient coverage.5, 6  
Therefore, it is possible that only individuals with more severe epilepsy were 
included. By using two primary care datasets, we have demonstrated that increased 
risks extend to people with epilepsy in the community. Only one other study has 
estimated the specific risk of accidental poisoning. The reported odds ratio (5.1, 
95%CI, 3.9-6.5)6 was similar to our meta-analyzed estimate.
Reasons for the increased risk of accidental death may include direct consequences 
of seizures3 or be unrelated to epilepsy. The mental illness comorbidities associated 
with epilepsy are also associated with increased risk of accident28 and suicide.29 
Indeed we saw greater proportions of people in the epilepsy cohort with mental 
health diagnoses at baseline and during follow-up, than the comparison cohort. 
There have been suggestions that suicidality and epilepsy share common 
neurological pathways,30 which could explain the increased risk of suicide. Clinicians 
should explore any symptoms of mental illness in people with epilepsy, and ask 
about thoughts of taking own life. Additionally, the psychosocial impact and stigma 
surrounding epilepsy may contribute to risk.31 It is possible that stigma or presence of
comorbid mental illness explains much of the three-fold elevation in homicide risk 
that we observed, an estimate congruent with that reported from a Swedish registry 
study (adjusted-OR 2.8, 95%CI 1.6-4.8).5
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The elevated risks identified for poisoning deaths might be attributable to the 
accessibility of medication in people with epilepsy, both AEDs and medication 
prescribed to treat comorbidities. The ease of access to means to take one’s own life
strongly influences suicide risk.32 However, AEDs were relatively infrequently 
recorded as being taken in accidental and intentional poisoning deaths among 
people with epilepsy. Our estimate that AEDs were taken in a tenth of poisonings is 
similar to Tian et al, who reported AED involvement in six percent of suicides among 
people with epilepsy.7 Many of the AEDs taken may have a lower relative toxicity 
than psychotropic drugs and opioids. This may have changed over time due to a 
reduction in use in phenobarbital,33 which historically contributed to over half of AED 
poisonings.34, 35 However, AEDs are frequently involved in non-fatal self-harm.8 
Ongoing vigilance is required to monitor nonfatal self-harm and poisoning deaths, as 
trends in AED prescribing change. ONS records report increasing involvement of 
gabapentin and pregabalin in poisoning deaths.36 This has been largely attributed to 
the diversion of pregabalin and gabapentin for recreational use.37 As these AEDs are
commonly used for treating conditions other than epilepsy, their involvement could 
extend beyond people with epilepsy.  
Our study meets the ILAE recommendations for defining epilepsy15 and classifying 
mortality by cause4 in epidemiologic studies. A major strength of our investigation is 
that we examined two large, linked, nationally representative primary care datasets. 
Our outcomes were identified from ONS mortality statistics, which is the most 
accurate method of ascertaining cause of death. These primary care datasets 
encompassed the whole spectrum of epilepsy, without restriction to more severe 
cases as in hospital-based cohorts. We applied a common study protocol across 
both datasets, to enable meta-analysis of relative risks even where observed event 
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counts were small. The elevated risk of intentional self-poisoning that was observed 
in the meta-analysis would not have been detected by utilizing only the SAIL 
Databank. Additionally, we verified our main findings by comparison with an incident 
epilepsy cohort. 
We are aware of potential limitations common to research using routinely collected 
data to investigate outcomes such as suicide. Firstly, the datasets are not generated 
primarily for the purpose of conducting research, and residual confounding may 
therefore be present. Secondly, some suicides may have been misclassified. We 
accounted for this by including unnatural deaths of undetermined intent in our suicide
definition. However, coroners in England and Wales have more frequently been 
using narrative verdicts to describe likely suicides in recent years, rather than 
assigning a specific verdict.38 Some of our meta-analyzed estimates were of low 
precision, due to the small event counts for the rarest cause-specific mortality 
outcomes. For this reason, we could not estimate risks for specific subgroups of 
unnatural death in the incident epilepsy cohort. We were unable to report the 
medication involvement for each dataset independently without compromising 
anonymity. Additionally, we could not subdivide the medications beyond that 
deducible from ICD-10 ‘T’ codes.
In summary, we have demonstrated that people with epilepsy have elevated risks for
most specific causes of unnatural death, including accidental and intentional 
poisoning by medication. Further research is needed to identify suitable measures to
mitigate these risks. In the meantime, clinicians should be aware of the elevated 
unnatural mortality risks and should carefully monitor patients accordingly. AEDs 
seemingly play a minor role in poisoning deaths, with psychotropic drugs and opioids
more often involved. Therefore, when prescribing to people with epilepsy, the 
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potential for poisoning and associated relative toxicity of concomitantly prescribed 
medication should be considered in light of the elevated fatal poisoning risk in this 
population.
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Table 1. Characteristics of epilepsy and comparison cohorts
Characteristics
CPRD SAIL Databank
Epilepsy cohort
 (n=44,678)
Comparison cohort
 (n=891,429)
Epilepsy cohort
 (n=14,051)
Comparison cohort 
(n=279,365)
Male 22,961 (51.4%) 458,008 (51.4%) 7,716 (51.1%) 142, 526 (51.0%)
Median age on entry (IQR)  41 (25-60)  40 (25-60)  44 (24-62)  43 (24-62)
Level of deprivationa
1 least deprived 7,621 (17.0%) 178,850 (20.1%) 2,202 (15.7%) 52,305 (18.7%)
2 8,878 (19.9%) 194,644 (21.8%) 2,314 (16.4%) 50,635 (18.1%)
3 8,565 (19.2%) 178,281 (20.0%) 3,059 (21.8%) 61,063 (21.9%)
4 9,723 (21.8%) 179,831 (20.2%) 2,997 (21.3%) 56,110 (20.1%)
5 most deprived 9,826 (22.0) 158,696 (17.8%) 3,468 (24.7%) 58,849 (21.1%)
Missing 65 (0.1%) 1,127 (0.1%) 11 (0.1%) 403 (0.1%)
Previous Diagnoses
Alcohol misusea 2,682 (6.0%) 12,056 (1.4%) 936 (6.7%) 5,823 (2.1%)
Anxietya 7,195 (16.1%)  104,532 (11.7%) 2,452 (17.5%) 34,486 (12.3%)
Bipolar disordera 465 (1.0%) 3,293 (0.4%) 143 (1.0%) 1,066 (0.4%)
Depressiona 9,096 (20.4%) 123,989(13.9%) 2,930 (20.9%) 39,953 (14.3%)
Eating disordera 548 (1.2%) 5,849 (0.7%) 183 (1.3%) 2,025 (0.7%)
Migrainea 3,081 (6.9%) 46,150 (5.2%) 1,058 (7.5%) 14,299 (5.1%)
Neuropathic pain 1,578 (3.5%) 30,763 (3.5%) 961 (6.8%) 18,253 (6.5%)
Personality disordera 836 (1.9%) 3,675 (0.4%) 307 (2.2%) 1,996 (0.7%)
Schizophreniaa 1,273 (2.9%) 6,711 (0.8%) 377 (2.7%) 2,584 (0.9%)
Self-harma 3,563 (8.0%) 23,248 (2.6%) 1,050 (7.5%) 9,140 (3.3%)
Substance misusea 2,972 (6.7%) 11,923 (1.3%) 1,122 (8.0%) 6,661 (2.4%)
Prior prescription at
baseline
Antidepressanta 11,175 (25.0%) 171,866 (19.3%) 4,043 (28.8%) 27,104 (20.4%)
Antipsychotica 6,823 (15.3%) 88,433 (9.9%) 1,843 (13.1%) 19,655 (7.0%)
Anxiolytic/hypnotica 14,562 (32.6%) 124,898 (14.0%) 4,938 (35.1%) 42,137 (15.1%)
Lithiuma 162 (0.4%) 1,982 (0.2%) 61 (0.4%) 642 (0.2%)
Opioida,b 14,355 (32.1%) 252,308 (28.3%) 6,603 (47.0%) 100,331 (35.9%)
Follow up
Median follow-up timea 4.0 (IQR 1.4-8.4) 5.1 (IQR 2.1-9.3) 6.9 (2.9-10.3) 7.7 (3.6-10.9)
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Table 1. Characteristics of epilepsy and comparison cohorts continued
Characteristics
CPRD SAIL Databank
Epilepsy cohort
 (n=44,678)
Comparison cohort
 (n=891,429)
Epilepsy cohort
 (n=14,051)
Comparison cohort 
(n=279,365)
New diagnoses during
follow-up
Alcohol misusea 784 (1.8%) 9,321 (1.1%) 296 (2.1%) 3,887 (1.4%)
Anxietya 2,901 (6.5%) 45,429 (5.1%) 1,069 (7.6%) 19,495 (7.0%)
Bipolar disordera 204 (0.5%) 1,595 (0.2%) 69 (0.5%) 535 (0.2%)
Depressiona 2,858 (6.4%) 46,189 (5.2%) 1,081 (7.7%) 18,892 (6.8%)
Eating disordera 383 (0.9%) 3,796 (0.4%) 176 (1.3%) 1,667 (0.6%)
Migraine 975 (2.2%) 17,155 (1.9%) 331 (2.4%) 6,536 (2.3%)
Neuropathic pain 1,217 (2.7%) 23,349 (2.6%) 729 (5.2%) 14,540 (5.2%)
Personality disordera 212 (0.5%) 963 (0.1%) 92 (0.7%) 706 (0.3%)
Schizophreniaa 465 (1.0%) 2,861 (0.3%) 213 (1.5%) 1,879 (0.7%)
Self-harma 846 (1.9%) 6,497 (0.7%) 322 (2.3%) 3,382 (1.2%)
Substance misusea 1,913 (4.3%) 25,016 (2.8%) 315 (2.2%) 3,518 (1.3%)
Reason for end of follow-
upa
Death identified from ONS 6,599 (14.8%) 62,903 (7.1%) 2,143 (15.3%) 23,540 (8.4%)
Practice stopped
contributing
7,175 (16.0%) 170,882 (19.1%) 6,330 (45.0%) 60,484 (21.7%)
Study end 16,623 (37.2%) 403,717 (45.3%) 5,578 (39.7%) 195,341 (69.9%)
Patient transferred out of
practice
14,281 (32.0%) 253,927 (28.5%) N/A N/A
asignificant (p<0.05) difference between epilepsy and comparison cohorts bincludes single prescriptions of opioids for acute pain relief e.g. co-codamol 
8mg/500mg
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Cause of death CPRD SAIL Databank
Epilepsy
 (n=44,687; PYs=232,095)
Comparison cohort 
(n=891,429; PYs=5,272,571)
Epilepsy cohort 
(n=14,051; PYs=93,972)
Comparison cohort 
(n=279,365; PYs=2,044,922)
Number rate /
100,000
PYs
95% CI Number rate/
100,000
PYs
95% CI Number rate/
100,000
PYs 
95 %CI Number rate/
100,000
PYs
95% CI
All deaths 6,559 2826.0 2758.0-
2895.2
62,903 1193.0 1183.7-
1202.3
2,143 2280.5 2184.9-
2379.1
23,540 1151.1 1136.5-
1165.9
Natural 6,406 2760.0 2692.9-
2828.5
61,127 1159.3 1151.0-
1168.6
2,065 2197.5 2103.7-
2294.3
22,821 1116.0 1101.6-
1130.6
Unnatural 193 83.1 71.8-95.8 1,776 33.7 32.1-35.3 78 83.0 65.6-
104.0
719 35.2 32.6-37.8
Accident 134 57.7 48.4-68.4 1,279 24.3 23.0-25.6 58 61.7 46.9-79.8 493 24.1 22.0-26.3
Transport accident 13 5.6 3.0-9.6 225 4.3 3.7-4.9 8 8.5 3.7-16.8 69 3.4 2.6-4.3
Other accident 93 40.7 32.3-49.1 936 17.8 16.6-18.9 41 43.6 31.3-59.1 361 17.7 15.9-19.6
Accidental medicine
poisoning
24 10.3 6.6-15.4 90 1.7 1.4-2.1 8 8.5 3.7-16.8 53 2.6 1.9-3.4
All accidental
poisoning
28 12.1 8.0-17.4 118 2.2 1.9-2.7 9 9.6 4.4-18.1 63 3.1 2.4-3.9
Suicide 47 20.3 14.9-26.9 407 7.7 7.0-8.5 16 17.0 9.7-27.7 199 9.7 8.4-11.1
Suicide poisoning
with medication
26 11.2 7.3-16.4 80 1.5 1.2-1.9 <5 N/A N/A 48 2.4 1.7-3.1
All suicide poisoning 26 11.2 7.3-16.4 100 1.9 1.5-2.3 <5 N/A N/A 54 2.6 2.0-3.5
Other suicide 21 9.1 5.6-13.8 307 5.8 5.2-6.5 12 12.8 6.6- 22.3 145 7.1 6.0-8.3
Homicide <5 N/A N/A 18 0.3 0.2-0.5 <5 N/A N/A 9 0.4 0.2-0.8
Iatrogenic 9 3.9 1.8-7.4 72 1.4 1.1-1.7 <5 N/A N/A 18 0.9 0.5-13.9
Table 2. Event counts and mortality rates for cause-specific unnatural mortality in prevalent epilepsy and comparison cohorts
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Figure 1. Flow diagram showing delineation of epilepsy and comparison cohorts. The identification of epilepsy and 
comparison cohorts from the SAIL Databank and the CPRD. Individuals who did not meet the cohort definition criteria were 
excluded at certain stages of cohort construction. 
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Figure 2. Forest plot showing deprivation-adjusted hazard ratios for cause-
specific unnatural mortality. Deprivation-adjusted hazard-ratios, for cause-specific 
mortality in the prevalent epilepsy cohort versus comparison cohort. Hazard ratios 
were estimated separately in the CPRD and SAIL and meta-analyzed using the 
DerSimonian and Laird random effects model. 
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Figure 3. Forest plot showing deprivation-adjusted hazard ratios estimated 
from prevalent and incident epilepsy cohorts. Deprivation-adjusted hazard ratios 
for all deaths, unnatural death, accidental death and suicide are shown for prevalent 
and incident epilepsy cohort, versus comparison cohorts. Hazard ratios were 
estimated separately in the CPRD and SAIL and meta-analyzed using the 
DerSimonian and Laird random effects model.
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Online Material. Risk of unnatural mortality in people with epilepsy
Hayley C Gorton, Roger T Webb, Matthew J Carr, Marcos del Pozo Baños, Ann 
John, Darren M Ashcroft
Explanation of the matching process applied to delineate the matched-cohort 
study
Separately in the CPRD and the SAIL Databank, people with epilepsy were matched to up to 20 
individuals who had never received a diagnostic code for epilepsy and were alive on the date that 
follow-up began. They were matched on gender, year of birth (+/-2 years) and registered general 
practice; and followed up from the same day as the corresponding individual in the epilepsy cohort. 
We employed an algorithm that used nearest-neighbor matching. Individuals were ineligible for 
inclusion in the comparison cohort if they ever had a diagnostic code for epilepsy. In both the epilepsy
and comparison cohorts, at least one day of follow-up after the entry date was required.  The 
matching ratio of up to 20:1 was used to improve statistical power to detect rare outcomes, in line with
evidence reported by Hennessy et al. that there are benefits to increasing the matching ratio for case-
control studies above 5:1 when the exposure prevalence is low among control subjects. (1) Therefore,
an increased matching ratio will be beneficial for the matched cohort design when incidence is very 
low in the comparison cohort. It enables more precise estimation of relative risks for exceptionally rare
specific causes of death such as homicide. Whilst this matching ratio was desired, in practice it was 
not possible to match all individuals with epilepsy to 20 people. This was because there were not 
enough individuals who were the same gender, had the same year of birth (+/- 2 years), were 
registered in the same general practice and who had never had a diagnosis of epilepsy. Each 
individual was matched to as many individuals as possible who satisfied the matching criteria. In the 
CPRD there was a median of 19 (IQR 18-19) individuals in the comparison cohort for each individual 
in the epilepsy cohort. The median was 20 (IQR 20-20) in the SAIL Databank. 
Reference:
i) Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-to-case 
ratio in matched case–control studies. Am J Epidemiol. 1999;149(5):489.
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e-Table 1. ICD-10 codes used to classify medication taken in fatal poisonings
Medication Group Codes
Psychotropic medication T40.5, T40.7, T40.8, T40.9, T42.4, T43.0-9, T50.5
Opioid T40.0-4, T40.6
Non-opioid T39
Antiepileptic Drugs T42.0-3, T42.5-7
Other T36-38,T41,T42.8,T44-49,T50.0-4, T50.6-9
ICD-10 codes listed in supplementary cause of death fields in the ONS mortality record
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Figure e-1. Kaplan-Meier plot depicting probability of cause-specific survival in 
relation to unnatural mortality in the CPRD
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Figure e-2. Kaplan-Meier plot depicting probability of cause-specific survival in 
relation to unnatural mortality in the SAIL Databank
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